Eli Lilly’s Sales Slash… And How To Position Ahead Of Bank Results 1/14/25
CNBC's "Fast Money"
00:00
Intro
This chapter explores Eli Lilly's recent stock price drop after an unfavorable Q4 revenue forecast, marking its worst performance since 2021. The impact on competitors like Novo Nordisk and Viking Therapeutics, as well as broader market reactions, are also examined.
Play episode from 00:00
Transcript
